Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296005 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL16414228 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL22341005 | 0.95 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL20705116 | 0.90 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL23290798 | 0.90 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| Oxalic Acid SCHEMBL23290975 | 0.79 | FFAR3 (0.32) | SMN1; SMN2 | |
| Oxalic Acid SCHEMBL23290977 | 0.79 | FFAR3 (0.32) | SMN1; SMN2 | |
| Oxalic Acid SCHEMBL31109890 | 0.79 | FFAR3 (0.32) | SMN1; SMN2 | |
| SCHEMBL22295920 | 0.76 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL20712762 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | SMN1; SMN2 124/4885KDM4E 2544/4885LMNA 246/4885 |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | SMN1; SMN2 124/4885KDM4E 2544/4885LMNA 246/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | SMN1; SMN2 124/4885KDM4E 2544/4885LMNA 246/4885 |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | SMN1; SMN2 124/4885KDM4E 2544/4885LMNA 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.